On January 5, 2022 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually on January 10-13, 2022 (Press release, Leap Therapeutics, JAN 5, 2022, View Source [SID1234598256]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on Monday, January 10 at 7:00 a.m. Eastern Time and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

On January 5, 2022 Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, reported its participation in two investor conferences as follows (Press release, Aeglea BioTherapeutics, JAN 5, 2022, View Source [SID1234598255]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference: 40th Annual J.P. Morgan Health Care Conference, January 10-13, 2022
Live Presentation Date/Time: Wednesday, January 12 at 10:30 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and CEO
Webcast: View Source;kiosk=true

Conference: H.C. Wainwright Bioconnect Virtual Conference, January 10-13, 2022
On Demand Presentation Date/Time: Monday, January 10 at 7:00 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and CEO
Webcast: View Source

To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company’s website. A replay of Company webcasts is archived on the website for 30 days following presentations.

On January 5, 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that they are scheduled to deliver a corporate presentation at the following virtual conferences (Press release, Autolus, JAN 5, 2022, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-present-conferences-during-january-2022 [SID1234598254]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Lucinda Crabtree, Senior Vice President, Finance, will present at the H.C. Wainwright BioConnect Conference, where an on-demand webcast will be available on Monday, January 10, 2022, starting at 7.00 am ET.

Dr. Christian Itin, Chief Executive Officer, will present at the 40th annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 8.15 am ET.
Senior management will participate in virtual one-on-one meetings with investors at both conferences.

The presentations will be available on the investor relations section of Autolus’ website at View Source An archived replay will be available on the company’s website for a period of 90 days after the conferences.

On January 5, 2022 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time (Press release, Affimed, JAN 5, 2022, View Source [SID1234598252]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed on Affimed’s website at View Source or at View Source;kiosk=true and will be available for 30 days following the event. For more information or to schedule a one-on-one meeting with Affimed management, please contact Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.

On January 5, 2022 Biogen Inc. (Nasdaq: BIIB) reported that it will present at the 40th Annual J.P. Morgan Healthcare Conference (Press release, Biogen, JAN 5, 2022, View Source [SID1234598249]). The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at investors.biogen.com. An archived version of the webcast will be available following the presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!